Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Red meat intake, CYP2E1 and PPARγ polymorphisms, and colorectal cancer risk.
|
30489355 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, the miR-211/FABP4/PPARγ axis may be a novel target for CRC therapy.
|
30809808 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed a series of chiral phenoxyacetic acid analogues for their ability to inhibit colorectal cancer (CRC) cells growth by binding PPARγ as partial agonists as assessed in transactivation assays of a PPARG-reporter gene.
|
30931956 |
2019 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PPARG have also been reported in sporadic colorectal cancers, but the significance of these mutations is unclear.
|
30595551 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Functional variants in the <i>peroxisome proliferator-activated receptor gamma</i> (<i>PPARG</i>) and <i>PPARG co-activator 1</i> (<i>PPARGC1</i>) family (e.g., <i>PPARGC1A</i> and <i>PPARGC1B</i>) genes were predicted to confer susceptibility to colorectal cancer (CRC).
|
30838172 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also evaluated the roles of PPARγ and PGC-1α as prognostic factors in colorectal cancer.
|
29566941 |
2018 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Obese and CRC patients had significantly low levels of PPARγ.
|
28878369 |
2017 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined whether the expression of NFATc2 and PPARG genes is significantly altered during the carcinogenesis of CRC.
|
28504924 |
2017 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, we identified a panel of proteins correlated with PPARγ expression that could be associated with CRC unveiling new pathways to be investigated for the selection of novel potential prognostic/predictive biomarkers and/or therapeutic targets.
|
27499265 |
2016 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis has established that ADH1B (rs1229984) and PPARG (rs1801282) are two risk variants of CRC.
|
24552298 |
2014 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach for treatment of colorectal cancer.
|
24975132 |
2014 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
|
25075794 |
2014 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that miR-145 is a novel target of PPARγ, acts as a tumor suppressor in CRC cell lines and is a key regulator of intestinal cell differentiation by directly targeting SOX9, a marker of undifferentiated progenitors in the colonic crypts.
|
24631504 |
2014 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling.
|
24133572 |
2013 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Thus, codeficiency of Cav1 and adenomatous polyposis coli facilitated formation of CRC, and activation of PPARg may offer novel strategies for treatment of CRC.
|
23640045 |
2013 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results provide new evidence of association between PPARG variants and colorectal cancer risk.
|
24045924 |
2013 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since higher levels of miR-130b are found in advanced tumor stages (III-IV), we propose a novel role of the miR-130b-PPARγ axis in fostering the progression toward more invasive CRCs.
|
24027433 |
2013 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the relationship between UHRF1 and PPARG may have a relevant role in CRC progression.
|
22286757 |
2012 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we provide the first evidence that elevated PPARδ expression and/or activation of PPARδ antagonize the ability of PPARγ to induce colorectal carcinoma cell death.
|
21765467 |
2012 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the Ala allele of the PPARgamma P12A polymorphism might be a protective factor for colorectal cancer, but a risk factor for gastric cancer.
|
20596649 |
2010 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study shows that PPARgamma agonists up-regulate KLF4 expression in receptor-dependent manner, and KLF4 was identified as a novel transcription factor that controls NAG-1 promoter activity in human and mouse colorectal cancers.
|
20385121 |
2010 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Remarkably, the same methylation pattern is found in PPARG-negative CRC cell lines.
|
21151932 |
2010 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence for the association between PPAR-gamma 34 C>G and CRC if all of the subjects in the nine studies were included.
|
20440859 |
2010 |
Colorectal Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We report a novel PPARG germline mutation in a patient affected by colorectal cancer that replaces serine 289 with cysteine in the mature protein (S289C).
|
20123124 |
2010 |